Andrea Henrich
Overview
Explore the profile of Andrea Henrich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
42
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cosson V, Fu R, Kulasekararaj A, Nishimura J, Panse J, Roth A, et al.
Br J Clin Pharmacol
. 2025 Jan;
PMID: 39835421
Aims: Crovalimab is a novel C5 inhibitor administered first intravenously and then subcutaneously in patients with paroxysmal nocturnal haemoglobinuria (PNH) naive to complement inhibition or switching from eculizumab or ravulizumab....
2.
Hsin C, Dingemanse J, Henrich A, Bernaud C, Gehin M, Krause A
Biomolecules
. 2023 Sep;
13(9).
PMID: 37759765
The P2Y receptor antagonist selatogrel is being developed for subcutaneous self-administration with a ready-to-use autoinjector at the onset of acute myocardial infarction (AMI) symptoms. The unique pharmacological profile of selatogrel...
3.
Bianzano S, Henrich A, Herich L, Kalsch B, Sarubbi D, Seitz F, et al.
Metabolism
. 2023 Mar;
143:155550.
PMID: 36958671
Background: Obesity is a complex disease associated with multiple concurrent complications, and the coordinated targeting of multiple pathways in pharmacological treatment may improve weight loss outcomes. During synthesis, ghrelin is...
4.
Ojara F, Henrich A, Frances N, Nassar Y, Huisinga W, Hartung N, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Feb;
12(11):1714-1725.
PMID: 36782356
Paclitaxel/platinum chemotherapy, the backbone of standard first-line treatment of advanced non-small cell lung cancer (NSCLC), exhibits high interpatient variability in treatment response and high toxicity burden. Baseline blood biomarker concentrations...
5.
Schilling U, Henrich A, Muehlan C, Krause A, Dingemanse J, Ufer M
Clin Drug Investig
. 2021 Jul;
41(8):711-721.
PMID: 34331678
Background And Objective: Daridorexant is a new dual orexin receptor antagonist currently in late-stage clinical development for the treatment of insomnia. This randomized, double-blind, placebo-controlled, four-period crossover study investigated the...
6.
Henrich A, Claussen C, Dingemanse J, Krause A
CPT Pharmacometrics Syst Pharmacol
. 2021 May;
10(7):735-747.
PMID: 33955698
Selatogrel is a potent and reversible P2Y receptor antagonist developed for subcutaneous self-administration by patients with suspected acute myocardial infarction. After single-dose emergency treatment with selatogrel, patients are switched to...
7.
Huynh C, Henrich A, Strasser D, Boof M, Al-Ibrahim M, Zu Schwabedissen H, et al.
Clin Pharmacol Ther
. 2021 Jan;
109(6):1648-1659.
PMID: 33406277
The C-X-C chemokine receptor 7 (CXCR7) has evolved as a promising, druggable target mainly in the immunology and oncology fields modulating plasma concentrations of its ligands CXCL11 and CXCL12 through...
8.
Henrich A, Juif P, Dingemanse J, Krause A
J Pharmacokinet Pharmacodyn
. 2021 Jan;
48(2):213-224.
PMID: 33389549
Clazosentan's potential QT liability was investigated in a thorough QT study in which clazosentan was administered intravenously as a continuous infusion of 20 mg/h immediately followed by 60 mg/h. Clazosentan...
9.
Ojara F, Henrich A, Frances N, Huisinga W, Hartung N, Joerger M, et al.
J Pharmacol Exp Ther
. 2020 Oct;
375(3):430-438.
PMID: 33008871
Paclitaxel-associated peripheral neuropathy (PN), a major dose-limiting toxicity, significantly impacts patients' quality of life/treatment outcome. Evaluation of risk factors often ignores time of PN onset, precluding the impact of time-dependent...
10.
Krause A, Henrich A, Dingemanse J
J Clin Pharmacol
. 2019 Sep;
60(3):369-377.
PMID: 31552685
The current trend for clinical pharmacology is toward more complex studies (eg, umbrella protocols covering single and multiple ascending doses, food effect, metabolism pathways), requiring many decisions to be made...